Understanding GLP-1 Medications, Costs, Side-Effects and Long-Term Change

The common “GLP-1 drugs” people talk about are brand names. The chemical names are the active pharmaceutical ingredients. Here are the main ones on the UK and global market.

Semaglutide

Brand names include Wegovy and Ozempic.

Semaglutide is a synthetic GLP-1 receptor agonist. That means it mimics the hormone GLP-1, which stands for glucagon-like peptide-1. The molecule is modified from native human GLP-1 to last longer in the body. Natural GLP-1 lasts minutes. Semaglutide lasts about a week.

Liraglutide

Brand name Saxenda and Victoza.

Liraglutide is also a synthetic GLP-1 receptor agonist. It is structurally similar to human GLP-1 but modified with a fatty acid chain to extend its half-life. It is injected daily rather than weekly.

Tirzepatide

Brand name Mounjaro.

Tirzepatide is slightly different. It is a dual GIP and GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide. So tirzepatide stimulates two incretin pathways, not one. That dual action is why it is sometimes called a “twincretin.”

Dulaglutide

Brand name Trulicity.

Another GLP-1 receptor agonist. It is structurally larger and designed for weekly dosing.

Exenatide

Brand name Byetta and Bydureon.

Exenatide is based on exendin-4, a peptide originally isolated from Gila monster venom. Biology is strange and wonderful. It also acts on the GLP-1 receptor.

In short:

Semaglutide

Liraglutide

Tirzepatide

Dulaglutide

Exenatide

All act on incretin pathways. Most are GLP-1 receptor agonists. Tirzepatide hits both GLP-1 and GIP.

Underneath the brand marketing, these are peptide hormones engineered to last longer in circulation and amplify appetite and glucose signalling pathways. The chemistry matters because duration of action, receptor selectivity, and dosing frequency all stem from those molecular tweaks.

GLP-1 medications like Wegovy, Ozempic, Saxenda, and Mounjaro have become widely used for weight and metabolic management around the world. The UK private market shows monthly costs that range from about £149 to £269 for Wegovy and Ozempic at common doses. Daily cost breaks down to roughly £5 to £9 per day. Saxenda, given daily, can range from about £3 to £13 per day based on pack size. Mounjaro ranges from around £4 to £8 per day depending on dose.

These prices are real money for most people. They are part of the decision when someone weighs the value of a treatment.

These drugs work by affecting appetite signals and slowing digestion. Many people see a weight change while using them. But the science does not show that the weight stays off long-term if the medication is stopped and habits are unchanged. In clinical studies, when the medication stops, and old eating patterns return, weight tends to return too.

That is not about blame or shame. It is about understanding cause and effect. The medication changes physiology. It does not on its own teach skills for eating, thinking about food, or responding to stress and cues in daily life.

If your goal is lasting weight change and improved metabolic health, two pathways matter at the same time:

• How your body responds to food, hormones, movement, sleep, stress and the drug.

• How you behave around food and activity in daily life.

Both matter. One without the other often means the change is temporary.

This is supported in published research. Studies show that when GLP-1 therapy is stopped, weight returns toward baseline unless lifestyle changes are maintained. There is no hidden agenda in the data. It is a clear pattern that repeats in multiple trials.

A strong food relationship means you work on patterns like:

• Understanding hunger and fullness signals.

• Recognising emotional triggers for eating.

• Structuring meals that support your goals.

• Building movement habits that fit your life.

• Planning ahead for social eating and stress.

• Improving sleep and stress balance.

These are skills, not quick fixes. They take time and effort. They build resilience and control.

GLP-1 medications can be a tool. They can provide support while you adapt behaviours. They can help reduce appetite, support adherence to a plan, and make early change more accessible. Many people find they get earlier success and momentum.

But the evidence says that when you stop the drug and do nothing different in your habits, the changes are unlikely to hold. That is not a failure in you. It is a fact of how the body stores energy and how behaviour reinforces patterns.

If you are considering GLP-1 medications, think of them in the context of a broader approach. Use them while you learn new skills.

Change your relationship with food. Build new habits. Learn the triggers that shape your eating. These are the factors that determine longer term weight and health outcomes.

You get to choose the path that fits your life. Understanding the limits and strengths of each

tool helps you make informed choices.

The Uncomfortable Part

These drugs act on gut hormones. They slow gastric emptying. They alter appetite signalling in the brain. They influence insulin and glucagon. When you manipulate those systems, effects follow. Some are expected. Some are less comfortable. A few are serious.

Common side effects

Nausea

This is the most reported effect. It often appears during dose escalation. It happens because food stays in the stomach longer and appetite signals change. For some people it settles. For others it persists.

Vomiting

Less common than nausea but still frequent enough to matter. Repeated vomiting can lead to dehydration.

Diarrhoea

Common during early weeks. Gut motility changes. Fluid shifts.

Constipation

Also common. Slower gastric emptying can mean slower bowel transit.

Abdominal pain and bloating

The gut feels full for longer. Gas and pressure build.

Reduced appetite

This is the intended mechanism. But in some people it becomes aversion to food rather than controlled hunger.

Fatigue

Often reported in the first few weeks. Reduced calorie intake also contributes.

Hair thinning

Rapid weight loss can trigger telogen effluvium, a temporary hair shedding phase.

Loss of lean muscle mass

Weight loss is not pure fat. Without resistance training and adequate protein, muscle loss occurs. This affects long term metabolic rate.

Gallstones

Rapid weight loss increases the risk. This is well documented across weight loss methods, not only GLP-1 drugs.

Less common but significant side effects

Pancreatitis

Inflammation of the pancreas. Rare, but serious. Symptoms include severe abdominal pain that radiates to the back. Evidence shows low absolute risk, but the association exists and is monitored.

Gallbladder disease

Includes gallstones and cholecystitis. Risk rises with rapid weight reduction.

Hypoglycaemia

More likely when combined with other diabetes medications. On their own, GLP-1 drugs rarely cause low blood sugar in non-diabetics.

Kidney injury

Usually secondary to dehydration from vomiting or diarrhoea.

Increased heart rate

Small but measurable increase in resting pulse has been observed.

Psychological effects

Some individuals report low mood, anxiety, or altered reward response. Research is still developing in this area. Appetite and reward circuits overlap with mood pathways.

Rare but serious concerns

Thyroid C-cell tumours

In rodent studies, GLP-1 receptor agonists increased the risk of medullary thyroid carcinoma. This has not been clearly demonstrated in humans, but a theoretical risk remains. These drugs are contraindicated in people with personal or family history of medullary thyroid cancer or MEN2 syndrome.

Severe allergic reactions

Rare but possible with any biologic medication.

Intestinal obstruction or severe gastroparesis

Because these drugs slow gastric emptying, there is ongoing research into whether prolonged use may worsen or trigger severe motility disorders in susceptible individuals.

The uncomfortable truth

If someone uses these medications without changing eating patterns, stress coping strategies, sleep, and movement, the underlying drivers of weight gain remain. When the drug stops, appetite signalling returns to baseline. Studies show weight regain after discontinuation if lifestyle change is not sustained.

This is not a moral statement. It is physiology.

Another uncomfortable point is that thin does not automatically mean metabolically healthy. A person can lose weight while still having poor sleep, low muscle mass, high stress load, and poor nutrient intake.

Rapid weight loss without resistance training increases the proportion of lean tissue lost. Loss of muscle reduces resting metabolic rate. That sets up a harder maintenance phase later.

None of this means the drugs have no place. They are tools. For some people they reduce cardiometabolic risk. For others they improve glycaemic control dramatically.

The key variable is whether the medication is used as a bridge while building new habits, or as a standalone solution.

Biology rewards behaviour. Hormones respond to environment. Long term metabolic change depends on both.

When people focus only on the scale, they miss the wider system that determines whether the result lasts.

If you are on GLP-1 drugs and would like support in understanding nutrition and how to wean yourself off safely to create long-term habits and sustainable changes, please reach out to me. 

Sim